rc48-adc
mAbexperimentalADC
Clinical trial activity
127 trials · 61 clinical orgs · 0 marketing orgs
Phase 1
24
Phase 2
109
Phase 3
9
Phase 4
4
Earliest trial started Nov 1, 2015 (NCT02881138)
Timeline
Indications
Approved for
Studied for
- Adenoma, Bile Duct · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Diseases · Phase 2
- Breast Neoplasms · Phase 4
- Capecitabine · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 4
- Colorectal Neoplasms · Phase 4
- Cystectomy · Phase 4
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2/Phase 3
- Fallopian Tube Neoplasms · Phase 2
- Genes, erbB-2 · Phase 3
- Genital Neoplasms, Female · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Immune Checkpoint Inhibitors · Phase 2
- Immunoconjugates · Phase 2
- Immunotherapy · Phase 2
- Kidney Transplantation · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 2
- Mutation · Phase 1/Phase 2
- Neoadjuvant Therapy · Phase 4
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Paget Disease, Extramammary · Phase 2
- Pancreatic Neoplasms · Phase 2
- Probiotics · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Radiotherapy · Phase 2
- Renal Insufficiency · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Scrotum · Phase 2
- Solitary Kidney · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 3
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Ureteral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 4
- Urology · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2BINDING AGENT
Receptor tyrosine-protein kinase erbB-2 binding agent
- Unspecified targetBINDING AGENT
binding agent
- TubulinDISRUPTING AGENT
Tubulin disrupting agent
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068485 ↗
- ChEMBLCHEMBL5095273 ↗
Also known as
- rc48-adc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07311577 | Phase 2 | Jan 1, 2026 | Jiangsu Cancer Institute & Hospital |
| NCT07279597 | Phase 2 | Dec 10, 2025 | Huazhong University of Science and Technology |
| NCT07201675 | Phase 2 | Dec 1, 2025 | Shandong University |
| NCT07172217 | Phase 2 | Oct 1, 2025 | Shandong University |
| NCT07194005 | Phase 2 | Sep 4, 2025 | Fudan University |
| NCT07100184 | Phase 2 | Sep 1, 2025 | Peking University, RemeGen |
| NCT07142200 | Phase 2 | Sep 1, 2025 | Jiao Tong University |
| NCT07151560 | Phase 2 | Aug 30, 2025 | Wuhan University |
| NCT07159217 | Phase 2 | Aug 30, 2025 | Chinese Academy of Medical Sciences |
| NCT07117851 | Phase 2 | Aug 1, 2025 | Fudan University, Fujian Medical University |
| NCT07093866 | Phase 2 | Jul 20, 2025 | Nanjing University |
| NCT06966453 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | Pfizer |
| NCT06944496 | Phase 3 | May 15, 2025 | RemeGen |
| NCT06957561 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Sun Yat-Sen University |
| NCT06791070 | Phase 2 | Jan 31, 2025 | Fujian Medical University, Fujian Provincial Hospital, Guangzhou Medical University, Wenzhou Medical University, Zhejiang University |
| NCT07285941 | Phase 2 | Jan 4, 2025 | Chinese Academy of Medical Sciences |
| NCT06904573 | Phase 2 | Jan 1, 2025 | Sun Yat-Sen University |
| NCT06730373 | Phase 2 | Dec 10, 2024 | Shandong University |
| NCT06642545 | Phase 2 | Nov 1, 2024 | RemeGen |
| NCT06630871 | Phase 2 | Oct 31, 2024 | BeOne Medicines, Fujian Medical University, RemeGen |
Showing 20 of 127 trials
Page 1 / 7
Organizations
Research & Development (61)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RemeGen | For profit | 41 | 32 | 4 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 20 | 12 | 3 | 2015 |
| Sun Yat-Sen University | Academic/Hospital | 10 | 9 | 3 | 2020 |
| Fudan University | Academic/Hospital | 9 | 7 | 2 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 8 | 6 | 4 | 2020 |
| Jiao Tong University | Academic/Hospital | 8 | 5 | 3 | 2020 |
| Peking University | Academic/Hospital | 8 | 5 | 3 | 2015 |
| Shandong University | Academic/Hospital | 8 | 6 | 4 | 2020 |
| Tianjin Medical University | Academic/Hospital | 7 | 7 | 1 | 2021 |
| Nanjing Medical University | Academic/Hospital | 5 | 5 | 2 | 2022 |
| Central South University | Academic/Hospital | 4 | 2 | 3 | 2020 |
| Fujian Medical University | Academic/Hospital | 4 | 2 | 2 | 2020 |
| Seattle Genetics | For profit | 4 | 4 | 2 | 2022 |
| Henan Medical University | Academic/Hospital | 3 | 2 | 2 | 2020 |
| Jiangsu Cancer Institute & Hospital | Academic/Hospital | 3 | 2 | 2 | 2020 |
| Shanxi Medical University | Academic/Hospital | 3 | 1 | 2 | 2020 |
| Sichuan University | Academic/Hospital | 3 | 2 | 2 | 2020 |
| Southern Medical University | Academic/Hospital | 3 | 2 | 2 | 2021 |
| Zhejiang University | Academic/Hospital | 3 | 1 | 2 | 2020 |
| Anhui Medical University | Academic/Hospital | 2 | 0 | 2 | 2020 |
61 organizations
Page 1 / 4